TILOCOR LIFE SCIENCE
Tilocor Life Sciences is a principal investment firm. It is based in Luxembourg.
TILOCOR LIFE SCIENCE
Status:
Active
Technology used in webpage:
Nginx Peg Technic
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2009-12-08 | Therasis | Tilocor Life Science investment in Series A - Therasis | 12 M USD |
| 2009-11-20 | Xigen | Tilocor Life Science investment in Series B - Xigen | 20 M USD |
| 2005-09-06 | Xigen | Tilocor Life Science investment in Series A - Xigen | 21 M USD |
More informations about "Tilocor Life Science"
Tilocor Life Science investment portfolio | PitchBook
Sep 6, 2005 Tilocor Life Science's latest investment was on 08-Dec-2009 in Therasis, a company within the Biotechnology industry. Data Transparency. Meet our data hygiene team. …See details»
General
Explore Tilocor Life Science profile on Finallot - Tilocor Life Sciences is a Luxembourg-based principal investment firm. based in Bonnevoie, 2543 Luxembourg - with 3 Investments - with 1 …See details»
Tilocor Life Science | Investor | Mindmaps
Tilocor Life Science provides financial support for the Tilocor Group's newly created companies, acquisitions and investments. Co-founded by Professor Stefan Catsicas, former Vice …See details»
Tilocor Life Science investor portfolio, rounds & team
Tilocor Life Science Venture capital Claimed. Principal investment firm it is based in luxembourg. Overview. Portfolio (0) Notes. Recent News about Tilocor Life Science Edit.See details»
Tilocor Life Sciences - BioCentury Company Profiles - BCIQ
Tilocor Life Sciences - BioCentury Company Profiles for the biopharma industrySee details»
Tilocor Life Science Sàrl :: Luxembourg :: OpenCorporates
Free and open company data on Luxembourg company Tilocor Life Science Sàrl (company number B105215), 127, Rue de Mühlenbach L - 2168 LuxembourgSee details»
Venture capital targets Swiss biotech - SWI swissinfo.ch
Sep 7, 2005 Its investors now include Tilocor Life Sciences of Luxembourg, Initiative Capital, a venture fund owned by Banque Cantonale Vaudoise, which now join Zug-based Venture …See details»
Therasis Raises $12 Million - venturecapitaljournal.com
Dec 8, 2009 Therasis, Inc., a newly founded oncology drug discovery company, has secured $12 million in a Series A financing from Tilocor Life Science. The funds will allow the Company …See details»
Therasis gains $12M Series A cash - Fierce Biotech
Dec 8, 2009 A start-up biotech company with deep scientific roots in New York has garnered $12 million to get to work on a cancer platform. Therasis raised the Series A cash from Tilocor Life …See details»
Stefan Catsicas - Crunchbase Person Profile
Prof. Stefan Catsicas has been the Chief Technology Officer and Executive Vice President at Nestlé S.A. since September 1, 2013. Prof. Catsicas is the President and Founder at Tilocor …See details»
Stefan Catsicas | Lift Global
He is also the Founder and President of Tilocor Life Sciences Sàrl and has served as Chairman of Cellular Engineering as well as as Vice-President and Research Director at Swiss Federal …See details»
Tilocor Life Science - Investments, Portfolio & Company Exits
Tilocor Life Sciences is a principal investment firm. It is based in Luxembourg. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. Experience the …See details»
Tilocor Life Science - Updates, News, Events, Signals & Triggers
Tilocor Life Sciences is a principal investment firm. It is based in Luxembourg.See details»
Xigen Raises $20 Million - Fierce Biotech
Nov 20, 2009 Tilocor Life Science provides financial support and services for the Group's newly created companies, acquisitions and investments. More information is available at …See details»
Notice #231687 - patrinum.ch
Pressenti pour devenir le nouveau recteur de l’Université de Genève, il cocrée Tilocor Life Science, basé au Luxembourg, puis, dès 2011 il met ses compétences au service de la King …See details»
Tilocor Life Science - Tech Stack, Apps, Patents & Trademarks
Tilocor Life Sciences is a principal investment firm. It is based in Luxembourg. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. Experience the …See details»
Therasis Obtains $12 Million From Tilocor in Series A Round
NEW YORK, NY -- 12/08/09 -- Therasis, Inc., a newly founded oncology drug discovery company, has secured $12 million in a Series A financing from Tilocor Life Science. The funds will allow …See details»
Xigen - Crunchbase Company Profile & Funding
Organization. Xigen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Xigen has 3 investors including Tilocor Life …See details»
2025 life sciences and health care outlook: Navigating key
Jan 29, 2025 Key takeways. Host: Kulleni Gebreyes, Vice Chair and US Life Sciences and Health Care Industry Leader Presenters: Jay Bhatt, Managing Director, Deloitte Center for …See details»
Xigen raises $21M in first round - Fierce Biotech
Sep 5, 2005 Switzerland's Xigen garnered $21 million in its first round, with Tilocor Life Sciences, Venture Incubator and Initiative Capital joining as investors. Xigen has been …See details»